Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 2

Lidocaine 5% patch for localized neuropathic pain: progress for the patient, a new approach for the physician

Authors Hans G , Robert D, Verhulst J, Vercauteren M

Published 30 March 2010 Volume 2010:2 Pages 65—70


Review by Single anonymous peer review

Peer reviewer comments 3

Guy Hans1,2, Dominique Robert3, Johanna Verhulst2, Marcel Vercauteren1,2

1Department of Anesthesiology, 2Multidisciplinary Pain Center, 3Department of Intensive Care, Antwerp University Hospital, Edegem, Belgium

Abstract: Neuropathic pain (NeP) syndromes remain a difficult-to-treat medical entity. Despite a growing number of pharmacological and invasive analgesic therapies the results remain less than optimal because of insufficient analgesic efficacy and/or occurrence of pronounced side effects. Current guidelines propose the use of multimodal and balanced pharmacological therapies, focused on the underlying pathophysiological mechanisms (mechanistic approach). Lidocaine 5% patches are a new treatment option currently licensed for the treatment of postherpetic neuralgia. However, these patches can also be used for the treatment of different types of superficial NeP syndromes, such as diabetic polyneuropathy. Their therapeutic success, however, largely depends on the correct identification of appropriate patients and pain syndromes. This manuscript outlines the correct identification of patients and proper use of these patches in order to ensure as much as possible the therapeutic efficacy of this new treatment option.

Keywords: neuropathic pain, lidocaine, patch

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.